Embrex and Shenzhen Neptunus announce joint project

Embrex has delivered an Egg Remover system and an Inovoject system to Shenzhen Neptunus Interlong Bio-technique (SNI). These have been installed in SNI's human influenza vaccine manufacturing facility at High-Tech Industrial Park Guangming, Shenzhen.

The high-speed automated Egg Remover system identifies and removes infertile eggs and "early dead' embryos on days 9 to 11 of incubation.

The viable eggs then proceed for inoculation with the influenza virus using the Inovoject system, which injects eggs at a rate of approximately 30,000 eggs/hour.

The system is part of meeting the critical technical and regulatory needs of human flu vaccine producers in many countries, including a proprietary sanitation system which cleans needles after the injection of every egg, thus minimising cross-contamination between eggs.

The manufacturing facility, which has recently completed construction, is believed to be the largest and most advanced human influenza vaccine production facility in China.